

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of the claims in the application.

Claims:

1. **(Withdrawn)** A composition comprising a liposome or lipid complex and an entrapped active platinum compound, the liposome or lipid complex containing one or more lipids, wherein the active platinum compound to lipid ratio is from 1:50 to 1:2 by weight.
2. **(Withdrawn)** The composition of claim 1, wherein the active platinum compound to lipid ratio is from 1:50 to 1:5 by weight.
3. **(Withdrawn)** The composition of claim 1, wherein the active platinum compound to lipid ratio is from 1:50 to 1:10 by weight.
4. **(Withdrawn)** The composition of claim 1, wherein the active platinum compound is cisplatin.
5. **(Withdrawn)** The composition of claim 1, wherein the active platinum compound to lipid ratio is from 1:25 to 1:15 by weight.
6. **(Withdrawn)** The composition of claim 5, wherein the active platinum compound is cisplatin.
7. **(Withdrawn)** The composition of claim 6, the one or more lipids comprise DPPC.
8. **(Withdrawn)** The composition of claim 7, the one or more lipids comprise cholesterol.

9. **(Withdrawn-Currently Amended)** The composition of claim 7, the one or more lipids comprise 50-100 ~~[[90?]]~~ mol% DPPC and 0-50 mol% cholesterol.
10. **(Withdrawn)** The composition of claim 7, the one or more lipids comprise 50-65 mol% DPPC and 35-50 mol% cholesterol.
11. **(Currently Amended)** A process for making a platinum aggregate comprising the steps of:
- (a) combining an active platinum compound and ~~a hydrophobic matrix-carrying system~~ one or more lipid complex-forming lipids selected from the group consisting of sterols, phosphatidylcholines, and combinations thereof;
 - (b) establishing the mixture at a first temperature; and
 - (c) thereafter establishing the mixture at a second temperature, which second temperature is cooler than the first temperature;
- wherein the steps (b) and (c) are effective to increase the encapsulation of active platinum compound, wherein steps (b) and (c) are repeated for a total of two or more cycles.
12. **(Canceled)**
13. **(Original)** The process of claim 11, wherein the active platinum compound solution is produced by dissolving active platinum compound in a saline solution to form a platinum solution.
14. **(Currently Amended)** The process of claim 13, wherein the active platinum compound is cisplatin.
15. **(Canceled)**
16. **(Currently Amended)** The process of claim ~~[[15]]~~ 11, wherein the phosphatidylcholine is ~~lipids comprise~~ DPPC.

17. **(Currently Amended)** The process of claim [[15]] 16, wherein the sterol is one or more lipids ~~further comprise~~ cholesterol.

18. **(Currently Amended)** The process of claim 11, wherein the ~~hydrophobic matrix carrying system is produced by dissolving~~ one or more lipid complex-forming lipids are dissolved in ethanol to form a lipid solution and injecting the lipid solution into a aqueous medium containing active platinum compound.

19. **(Original)** The process of claim 11, further comprising sequentially repeating the steps (b) and (c) for a total of three or more cycles.

20. **(Original)** The process of claim 19, wherein the step (c) comprises establishing the mixture at a temperature from -25 degrees Celsius to 25 degrees Celsius.

21. **(Original)** The process of claim 19, wherein step (c) comprises establishing the mixture at a temperature from -5 degree Celsius to 5 degrees Celsius.

22. **(Original)** The process of claim 19, wherein the step (b) comprises establishing the mixture at a temperature from 4 degrees Celsius to 75 degrees Celsius.

23. **(Original)** The process of claim 19, wherein the step (b) comprises establishing the mixture at a temperature from 45 degrees Celsius to 55 degrees Celsius.

24. **(Original)** The process of claim 11, wherein the temperature differential between steps (b) and (c) is 25 degrees Celsius or more.

25. **(Original)** The process of claim 24, wherein the temperature established in step (b) is 50 degrees Celsius or more.

26. **(Original)** The process of claim 11, wherein the temperature established in step (b) is 50 degrees Celsius or more.

27. **(Original)** A platinum aggregate produced by the method of claim 11.

28. **(Original)** A platinum aggregate produced by the method of claim 14.

29. **(Withdrawn)** A pharmaceutical formulation comprising the composition of claim 1 and a pharmaceutically acceptable carrier or diluent.

30. **(Withdrawn)** A pharmaceutical formulation comprising the composition of claim 1, adapted for inhalation by a patient.

31. **(Withdrawn)** A pharmaceutical formulation comprising the composition of claim 1, adapted for injection into a patient.

32. **(Currently Amended)** The process of claim 11, further comprising, after all of steps (b) and steps (c) have been completed:

(d) removing un-entrapped active platinum compound by filtering through a membrane having a molecular weight cut-off selected to retain desired ~~liposomes or~~ lipid complexes and adding a ~~liposome or~~ lipid complex compatible liquid to wash out un-entrapped active platinum compound.

33. **(New)** The process of claim 11, wherein the temperature differential between steps (b) and (c) is 15 degrees Celsius or more.